Pemigatinib
- TRADE NAME: Pemazyre (Incyte)
- INDICATIONS: Unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.
- CLASS: Fibroblast growth factor receptor inhibitor, Kinase inhibitor
- HALF-LIFE: 15.4 hours
FDA APPROVAL DATE: 04/17/2020
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:CYP3A inducers, CYP3A inhibitors, Itraconazole, Rifampin
Can cause fetal harm. Advise patients of reproductive potential of the potential risk to the fetus and use effective contraception.
Pemigatinib can cause retinal pigment epithelial detachment. Perform ophthalmological examination including optical coherence tomography prior to initiation of therapy, every 2 months for the first 6 months of treatment and every 3 months thereafter, and urgently at any time for visual symptoms.
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
Page last updated 02/01/2021
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
